AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 – a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases
Jan. 2022
AffaMed Therapeutics Doses First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA in China in Cataract Surgery Patients
Jan. 2022
AffaMed Technologies Announces Successful Completion of First Patient Implantations of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in Boao, Hainan
Jan. 2022
AffaMed Therapeutics Enters into a Licensing Agreement with Hanmi Pharmaceutical to Develop and Commercialize Risuteganib (Luminate®) as a First-In-Class Treatment for Intermediate Dry AMD Patients in Greater China
2021
Nov. 2021
AffaMed Therapeutics Announces the Establishment of AffaMed Digital to Advance Digital Medicines
Nov. 2021
Supplemental New Drug Application for DEXTENZA Approved by FDA for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Oct. 2021
AffaMed Therapeutics' Joint Venture Launched in Beijing to Advance Industry-Leading Solutions for Cataract Surgery in Greater China
Sep. 2021
AffaMed Therapeutics Announces Completion of First Patient Dosing of AM006 for Early Parkinson's Disease
Sep. 2021
AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases
Sep. 2021
AffaMed Therapeutics and Allgenesis Biotherapeutics Announce License Agreement for AG-73305 in Greater China Region
May. 2021
AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson’s Disease
May. 2021
AffaMed Therapeutics Announces Appointment of Vijay Karwal as Chief Financial Officer
Mar. 2021
AffaMed Therapeutics and SIFI announce Joint Venture to serve Greater China Market
Mar. 2021
Affamed Therapeutics announces completion of over US$170 million series B financing and appoints Dr. Ji Li as President and Board Member
2020
Oct. 2020
AffaMed Therapeutics and Ocular Therapeutix announce license agreement and collaboration for DEXTENZA® and OTX-TIC in Asia
Oct. 2020
AffaMed Therapeutics and EverInsight Therapeutics merged with Dayao Zhao, M.D., Ph.D. appointed as CEO
Jun. 2020
EverInsight Therapeutics and VistaGen Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
2019
Aug. 2019
EverInsight Therapeutics established
Feb. 2019
AffaMed Therapeutics partners with Samsung Bioepis to develop and commercialize biosimilars in China
